The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference offers an unparalleled opportunity for Parkinson’s disease (PD) drug developers to hear the latest research results and build relationships that can lead to fruitful collaborations to benefit Parkinson’s patients.

“Never before have there been more promising clues to what may serve as a target for Parkinson’s therapies,” said conference chair C. Warren Olanow, MD, of the Mount Sinai School of Medicine. “The Michael J. Fox Foundation is right in the middle of that, and this conference provides a golden opportunity to learn about these targets.”

The Foundation’s seventh annual PD Therapeutics Conference will take place Thursday, October 24, in New York City. Held in partnership with the New York Academy of Sciences (NYAS), the event brings together approximately 250 research and business development professionals from academia and industry and showcases some of the most promising projects from MJFF’s research portfolio.

“Other funding supports research with preliminary data. What’s been lacking is support for high-risk, high-reward projects,” Olanow said. “The Michael J. Fox Foundation is fostering great ideas, and the PD Therapeutics Conference is a chance to see where that has led.”

Novel advances in disease-modifying treatments, symptomatic therapies, and research tools and resources are highlighted through speaker presentations and a poster session at the NYAS headquarters. Donald E. Frail, PhD, from AstraZeneca PLC, and Eric Siemers, MD, of Eli Lilly and Company, will give “Hot Topics” presentations on, respectively, drug repositioning and what the PD research community has learned from Alzheimer’s disease trials.

See the full agenda and register now on the New York Academy of Sciences Web site.